caramiphen

Caramiphen is a small molecule anticholinergic (cholinergic antagonist) drug primarily used in the treatment of Parkinson's disease and, in combination with phenylpropanolamine, as a cough suppressant and nasal decongestant for symptomatic relief of seasonal respiratory conditions such as colds, allergies, hay fever, and sinusitis. Its mechanism of action involves antagonism at muscarinic acetylcholine receptors—particularly the M1 subtype—thereby inhibiting cholinergic neurotransmission. Caramiphen also exhibits binding to sigma-1 receptors and has demonstrated anticonvulsant properties through modulation of NMDA (glutamate) receptor-mediated currents and facilitation of GABAergic inhibitory currents. It was first added to clinical use in the early 1960s[1][3][5][6].

Brand names

CarafenParpanilPanparnitPentaphen

Other names

caramiphenumcaramifeniocaramiphene